{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:06:17Z","timestamp":1784541977865,"version":"3.55.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The challenge of managing acute hypercalcemia in patients diagnosed with hypercalcemia of malignancy (HCM) merits further attention. Elevated levels of PTHrP may be a risk factor for treatment resistance in acute hypercalcemia; however, few studies have tested this hypothesis. This study aimed to investigate whether high PTHrP levels represent an independent risk factor that impedes the treatment of acute hypercalcemia. This retrospective cohort study recruited 159 patients aged 20-80\u00a0years with diagnosed malignancies who had been hospitalized for hypercalcemia with PTHrP levels above the reference value (1.1\u00a0pmol\/L). The median (25%-75%) patient age was 69 (61-76) years, and the median PTHrP level was 6.3 (3.3-11.1) pmol\/L. The corrected calcium levels decreased from 12.8\u00a0mg\/dL (11.9-14.1\u00a0mg\/dL) to 10.6\u00a0mg\/dL (9.8-11.7\u00a0mg\/dL) following treatments, such as bisphosphonates and saline solution. Multivariate linear regression analysis showed less significant decreases in the corrected calcium levels as natural logarithm-transformed PTHrP levels increased (\u03b2 coefficient [95% CI]: 0.569 [0.225-0.914]; p = .001 for Model 3). Multivariate logistic regression analysis showed an association between high natural logarithm-transformed PTHrP levels and lack of treatment response, defined as a corrected calcium level of \u226410.4\u00a0mg\/dL in the last blood test conducted within 2\u00a0wk of treatment initiation (odds ratio [95% CI]: 0.504 [0.312-0.814]; p = .005). Therefore, elevated PTHrP levels are a potential risk factor for treatment resistance in hypercalcemia in HCM patients, complicating management regardless of calcium levels.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziae178","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T12:23:46Z","timestamp":1736943826000},"source":"Crossref","is-referenced-by-count":1,"title":["Parathyroid hormone-related protein levels and treatment outcomes in hypercalcemia of malignancy: a retrospective cohort study"],"prefix":"10.1093","volume":"9","author":[{"given":"Kazuhiko","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Hypertension, The Jikei University School of Medicine , Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-0301","authenticated-orcid":false,"given":"Akio","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Hypertension, The Jikei University School of Medicine , Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Hypertension, The Jikei University School of Medicine , Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Hypertension, The Jikei University School of Medicine , Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Ohkido","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Hypertension, The Jikei University School of Medicine , Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Hypertension, The Jikei University School of Medicine , Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Hypertension, The Jikei University School of Medicine , Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"8","key":"2025022505562808100_ref1","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cam4.749","article-title":"Prevalence of hypercalcemia among cancer patients in the United States","volume":"5","author":"Gastanaga","year":"2016","journal-title":"Cancer Med"},{"issue":"4","key":"2025022505562808100_ref2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2025022505562808100_ref3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12032-019-1315-8","article-title":"Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysis","volume":"36","author":"Bhandari","year":"2019","journal-title":"Med Oncol"},{"issue":"7","key":"2025022505562808100_ref4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-112-7-499","article-title":"Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients","volume":"112","author":"Ralston","year":"1990","journal-title":"Ann Intern Med"},{"issue":"4","key":"2025022505562808100_ref5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.11005\/jbm.2017.24.4.249","article-title":"Clinical characteristics, causes and survival in 115 cancer patients with parathyroid hormone related protein-mediated hypercalcemia","volume":"24","author":"Jin","year":"2017","journal-title":"J Bone Metab"},{"issue":"6","key":"2025022505562808100_ref6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JGO.2016.006890","article-title":"Malignancy-related hypercalcemia in advanced solid tumors: survival outcomes","volume":"3","author":"Ramos","year":"2017","journal-title":"J Glob Oncol"},{"issue":"5","key":"2025022505562808100_ref7","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1210\/jc.2014-4250","article-title":"PTHrP-mediated hypercalcemia: causes and survival in 138 patients","volume":"100","author":"Donovan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025022505562808100_ref8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0002-9343(03)00310-3","article-title":"Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia","volume":"115","author":"Truong","year":"2003","journal-title":"Am J Med"},{"issue":"12","key":"2025022505562808100_ref9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.eprac.2024.09.003","article-title":"Association between parathyroid hormone-related peptide levels and mortality in patients with malignancy","volume":"30","author":"Kimura","year":"2024","journal-title":"Endocr Pract"},{"issue":"1","key":"2025022505562808100_ref10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.critrevonc.2005.04.004","article-title":"Metabolic emergencies","volume":"58","author":"Spinazz\u00e9","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"2025022505562808100_ref11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3322\/caac.20124","article-title":"Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment","volume":"61","author":"Lewis","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"2025022505562808100_ref12","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"15","key":"2025022505562808100_ref13","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJMcp2113128","article-title":"Cancer-associated hypercalcemia","volume":"386","author":"Guise","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"2025022505562808100_ref14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2025022505562808100_ref15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/1060028020957048","article-title":"Bisphosphonate versus bisphosphonate and calcitonin for the treatment of moderate to severe hypercalcemia of malignancy","volume":"55","author":"Khan","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2025022505562808100_ref16","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-20-0487","article-title":"Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift","volume":"10","author":"O'Callaghan","year":"2021","journal-title":"Endocr Connect"},{"issue":"8","key":"2025022505562808100_ref17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/07357907.2015.1047506","article-title":"Quality and outcomes of treatment of hypercalcemia of malignancy","volume":"33","author":"Wright","year":"2015","journal-title":"Cancer Investig"},{"issue":"8","key":"2025022505562808100_ref18","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/1097-0142(19940415)73:8&lt;2223::AID-CNCR2820730831&gt;3.0.CO;2-C","article-title":"Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate","volume":"73","author":"Wimalawansa","year":"1994","journal-title":"Cancer"},{"issue":"8861","key":"2025022505562808100_ref19","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/0140-6736(93)90756-7","article-title":"Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia","volume":"341","author":"Gurney","year":"1993","journal-title":"Lancet"},{"issue":"01","key":"2025022505562808100_ref20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1055\/s-2007-1002043","article-title":"Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955","volume":"25","author":"Blind","year":"1993","journal-title":"Horm Metab Res"},{"issue":"4","key":"2025022505562808100_ref21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/jbmr.5650090412","article-title":"Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein","volume":"9","author":"Budayr","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025022505562808100_ref22","doi-asserted-by":"publisher","first-page":"e1115","DOI":"10.1210\/clinem\/dgz278","article-title":"Calcitriol elevation is associated with a higher risk of refractory hypercalcemia of malignancy in solid tumors","volume":"105","author":"Chukir","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5893","key":"2025022505562808100_ref23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/bmj.4.5893.643","article-title":"Interpretation of serum calcium in patients with abnormal serum proteins","volume":"4","author":"Payne","year":"1973","journal-title":"Br Med J"},{"issue":"3","key":"2025022505562808100_ref24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10654-019-00494-6","article-title":"Principles of confounder selection","volume":"34","author":"VanderWeele","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"2025022505562808100_ref25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jcte.2018.05.004","article-title":"Incidence of hypocalcemia and hypercalcemia in hospitalized patients: is it changing?","volume":"13","author":"Catalano","year":"2018","journal-title":"J Clin Transl Endocrinol"},{"issue":"10","key":"2025022505562808100_ref26","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.2215\/CJN.02470312","article-title":"Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia","volume":"7","author":"Rosner","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"16","key":"2025022505562808100_ref27","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJM199004193221603","article-title":"Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer","volume":"322","author":"Burtis","year":"1990","journal-title":"N Engl J Med"},{"issue":"5034","key":"2025022505562808100_ref28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1126\/science.1658941","article-title":"A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide","volume":"254","author":"J\u00fcppner","year":"1991","journal-title":"Science"},{"issue":"9","key":"2025022505562808100_ref29","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1210\/jc.2012-2142","article-title":"Parathyroid hormone-related protein: an update","volume":"97","author":"Wysolmerski","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025022505562808100_ref30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2217\/fon.12.76","article-title":"The multifaceted actions of PTHrP in skeletal metastasis","volume":"8","author":"Soki","year":"2012","journal-title":"Future Oncol"},{"issue":"10","key":"2025022505562808100_ref31","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/ncb3408","article-title":"Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow","volume":"18","author":"Johnson","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2025022505562808100_ref32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/1078-0432.CCR-06-1487","article-title":"Parathyroid hormone-related protein induces cachectic syndromes without directly modulating the expression of hypothalamic feeding-regulating peptides","volume":"13","author":"Hashimoto","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025022505562808100_ref33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","article-title":"PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer","volume":"23","author":"Kir","year":"2016","journal-title":"Cell Metab"},{"issue":"4","key":"2025022505562808100_ref34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1359\/jbmr.2003.18.4.599","article-title":"Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics","volume":"18","author":"Zaidi","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"6 Suppl 21","key":"2025022505562808100_ref35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1053\/sonc.2002.37417","article-title":"Treatment of hypercalcemia of malignancy with bisphosphonates","volume":"29","author":"Berenson","year":"2002","journal-title":"Semin Oncol"},{"issue":"2","key":"2025022505562808100_ref36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1078155213518361","article-title":"Denosumab in hypercalcemia of malignancy: a case series","volume":"21","author":"Dietzek","year":"2015","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"2025022505562808100_ref37","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/EJE-14-0166","article-title":"Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab","volume":"171","author":"Karuppiah","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2025022505562808100_ref38","doi-asserted-by":"publisher","first-page":"bcr2013202861","DOI":"10.1136\/bcr-2013-202861","article-title":"Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy","volume":"2014","author":"Adhikaree","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"9","key":"2025022505562808100_ref39","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziae178\/61440585\/ziae178.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/3\/ziae178\/61440585\/ziae178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/3\/ziae178\/61440585\/ziae178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:58:03Z","timestamp":1740463083000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziae178\/7954317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziae178","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,1,15]]},"article-number":"ziae178"}}